Phase I trials have evolvedEU Legislative developments have redefined the boundaries of Phase I and opened a new era of opportunity to expedite compounds through the Early Phases. Pharmacology and patient studies can now be integrated or work independently of one another. Clinical & therapeutic innovations now enable Early Phase research to deliver more dynamic and insightful studies, maximizing the probability of a compound reaching the later Phases. We have put together the definitive one-day seminar to explore the new boundaries of Phase I.Click here for more information

Latest news

How Richmond Pharmacology Supports Sponsors Navigating ICH E6 (R3)

February 5, 2026
The updated ICH E6 (R3) guideline places greater emphasis on proportionality, risk-based oversight...
Read more

Events

Clinical Trials Innovation Programme

10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event